NDA 021358 · Bracco
Multihance Multipack
Gadobenate Dimeglumine · Intravenous
Last checked: Nov 20, 2026Latest source record: Mar 5, 2025 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations
First approved
2004
Nov 23, 2004
Approved uses
3
Original approval plus efficacy supplements
Registered trials
61
17 Phase 3, 1 recruiting
FAERS reports
4,411
2,714 serious, 208 with death reported
AI brief across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.
Boxed warning
WARNING: RISK ASSOCIATED WITH INTRATHECAL USE and NEPHROGENIC SYSTEMIC FIBROSIS Risk Associated with Intrathecal Use Intrathecal administration of gadolinium-based contrast agents (GBCAs) can cause serious adverse reactions including death, coma, encephalopathy, and seizures. MultiHance is not approved for intrathecal use [see Warnings and Precautions (5.1) ] . Nephrogenic Systemic Fibrosis GBCAs increase the risk for nephrogenic systemic fibrosis (NSF) among patients with impaired elimination of the drugs. Avoid use of MultiHance in these patients unless the diagnostic information is essential and not available with non-contrasted MRI or other modalities. NSF may result in fatal or debilitating systemic fibrosis affecting the skin, muscle and internal organs. The risk for NSF appears highest among patients with: chronic, severe kidney disease (GFR <30 mL/min/1.73m 2 ), or acute kidney...
What it is approved for
From the label in effect Mar 16, 2025.
magnetic resonance imaging (MRI) of the central nervous system (CNS) in adults and pediatric patients (including term neonates), to visualize lesions with abnormal blood-brain barrier or abnormal vascularity of the brain, spine, and associated tissues (1.1) magnetic resonance angiography (MRA) to evaluate adults with known or suspected renal or aorto-ilio-femoral occlusive vascular disease. (1.2) 1.1 Magnetic Resonance Imaging (MRI) of the Central Nervous System (CNS) MultiHance is indicated for intravenous use in magnetic resonance imaging (MRI) of the central nervous system (CNS) in adults and pediatric patients (including term neonates), to visualize lesions with abnormal blood-brain barrier or abnormal vascularity of the brain, spine, and associated tissues. 1.2 Magnetic Resonance Angiography (MRA) of Renal and Aorto-ilio-femoral Vessels MultiHance is indicated for use in magnetic resonance angiography (MRA) to evaluate adults with known or suspected renal or aorto-ilio-femoral occlusive vascular disease.
Mechanism: Gadobenate dimeglumine is a paramagnetic agent and, as such, develops a magnetic moment when placed in a magnetic field. The large magnetic moment produced by the paramagnetic agent results in a large local magnetic field, which can enhance the relaxation rates of water protons in its vicinity leading to an increase of signal intensity (brightness) of tissue. In magnetic resonance imaging (MRI), visualization of normal and pathological tissue depends in part on variations in the radiofrequency signal intensity that occur with 1) differences in proton density; 2) differences of the...
Approval history
Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.
- Jan 19, 2018 Supplement 13 · Efficacy LabelLetter
- Jul 6, 2012 Supplement 9 · Efficacy LabelLetter
- Nov 23, 2004 Original approval · Type 3 - New Dosage Form Other Important Information from FDAReviewLetter
2 products under this application
- MULTIHANCE MULTIPACK · GADOBENATE DIMEGLUMINE 52.9GM/100ML (529MG/ML) · INJECTABLE, INTRAVENOUS · Prescription
- MULTIHANCE MULTIPACK · GADOBENATE DIMEGLUMINE 26.45GM/50ML (529MG/ML) · INJECTABLE, INTRAVENOUS · Prescription
Clinical trials
Interventional ClinicalTrials.gov studies with "Gadobenate Dimeglumine" as an intervention, any sponsor and status, largest first.
GuerbetIndustry
NCT04373564 · 2,076 participants (planned) · Start Mar 24, 2021 · Primary completion Dec 31, 2028
Drug: Gadoxetate disodium; Gadobenate dimeglumine and 4 more · For: Motor Function; Cognitive Function; Contrast Media
Sites: Scottsdale, Arizona; New Haven, Connecticut; Chicago, Illinois · 51 sites in all
- Safety and Efficacy Evaluation of DOTAREM® in MRI of Central Nervous System (CNS) LesionsPivotal-lookingCompleted
GuerbetIndustry
NCT01211873 · 416 participants · Start Sep 2010 · Primary completion Nov 2011
Drug: Dotarem (gadoterate meglumine); Magnevist (gadopentetate dimeglumine) · For: Diagnostic Self Evaluation; Central Nervous System Diseases
Sites: Birmingham, Alabama; Tucson, Arizona; Indian Wells, California · 52 sites in all
- Gadobutrol Magnevist-controlled Body StudyPivotal-lookingCompleted
BayerBayer (BAYRY)
NCT01050829 · 370 participants · Start Jan 2010 · Primary completion Apr 2011
Drug: Gadobutrol (Gadovist, BAY86-4875); Gadopentetate Dimeglumine (Magnevist, BAY86-4882) · For: Magnetic Resonance Imaging
Sites: Nanjing, China; Suzhou, China; Xi’an, China · 15 sites in all
- Magnevist® Injection Enhanced MRA at Two Dose Levels Compared to Non Contrast MRA for the Detection of Structural Abnormalities of the Infrarenal Aorta and Peripheral ArteriesPivotal-lookingCompleted
BayerBayer (BAYRY)
NCT00185276 · 365 participants · Start Mar 2003
Drug: Gadopentetate dimeglumine (Magnevist, BAY86-4882); Gadopentetate dimeglumine (Magnevist, BAY86-4882) · For: Peripheral Vascular Disease
- P03277 Dose Finding Study in Central Nervous System (CNS) Magnetic Resonance Imaging (MRI)Pivotal-lookingCompleted
GuerbetIndustry
NCT02633501 · 312 participants · Start Jun 2016 · Primary completion Jan 2018
Drug: P03277; Gadobenate dimeglumine · For: CNS Lesion; Blood Brain Barrier Defect
Sites: Chicago, Illinois; Boston, Massachusetts; Farmington Hills, Michigan · 28 sites in all
- Crossover Comparison of MultiHance and DotaremPivotal-lookingCompleted
Bracco Diagnostics, IncIndustry
NCT02070380 · 179 participants · Start Feb 2014 · Primary completion Mar 2015
Drug: MultiHance 0.1 mmol/kg; Dotarem and 1 more · For: Brain Disease
Sites: Corvallis, Oregon
- Comparative Effectiveness of Gadopiclenol for Evaluation of Adult Congenital Heart Anatomy and HemodynamicsPivotal-lookingCompleted
University of California, San DiegoAcademic, hospital or other
NCT06406517 · 161 participants · Start Aug 5, 2024 · Primary completion Apr 23, 2026
Drug: Gadopiclenol; Gadobenate dimeglumine · For: Congenital Heart Disease
Sites: San Diego, California
- Efficacy and Safety Study to Evaluate Gadavist (Gadobutrol) as Contrast Agent in Magnetic Resonance Imaging (MRI) of Brain or Spine Diseases in Chinese PatientsPivotal-lookingCompleted
BayerBayer (BAYRY)
NCT00395460 · 147 participants · Start Sep 2006 · Primary completion Apr 2007
Drug: Gadobutrol (Gadavist, Gadovist, BAY86-4875); Magnevist · For: Central Nervous System Diseases
Sites: Nanjing, China; Xi'an, China; Beijing, China · 4 sites in all
Most reported adverse reactions
FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.
- pain623
- nausea598
- nephrogenic systemic fibrosis588
- vomiting513
- hypersensitivity437
- urticaria426
- anxiety384
- dyspnoea356
- injury356
- emotional distress337
- pruritus330
- arthralgia293
FAERS reports by year
By the date FDA received the report.
View as table
| Year | Reports |
|---|---|
| 2005 | 154 |
| 2006 | 124 |
| 2007 | 662 |
| 2008 | 54 |
| 2009 | 196 |
| 2010 | 245 |
| 2011 | 295 |
| 2012 | 135 |
| 2013 | 181 |
| 2014 | 249 |
| 2015 | 181 |
| 2016 | 203 |
| 2017 | 225 |
| 2018 | 229 |
| 2019 | 359 |
| 2020 | 344 |
| 2021 | 133 |
| 2022 | 77 |
| 2023 | 82 |
| 2024 | 77 |
| 2025 | 63 |
| 2026 | 143 |
Recalls
1 FDA enforcement reports for this application.
Apr 16, 2012 · Class II · Terminated
Lack of Assurance of Sterility; Product recalled due to displacement of the aluminum crimp cap during product usage.
Shortages
FDA's drug shortage list.
Not on FDA's shortage list.
Medicare spending
CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.
Part B: Multihance Multipack (Gadobenate Dimeglumine) · HCPCS A9578
2024 spending
$169K
Beneficiaries
6,056
6,704 claims
Per beneficiary
$28
2024 ASP limit $1.78 per unit
View as table
| Year | Spending |
|---|---|
| 2020 | $95,669 |
| 2021 | $107,242 |
| 2022 | $98,682 |
| 2023 | $135,341 |
| 2024 | $169,200 |
Published evidence
PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.
- Risk of Nephrogenic Systemic Fibrosis in Patients With Stage 4 or 5 Chronic Kidney Disease Receiving a Group II Gadolinium-Based Contrast Agent: A Systematic Review and Meta-analysis.
Woolen SA, Shankar PR, Gagnier JJ, et al. · JAMA Intern Med 2020 · Meta-Analysis, Systematic Review
- Detection of liver metastases on gadobenate dimeglumine-enhanced MRI: systematic review, meta-analysis, and similarities with gadoxetate-enhanced MRI.
Zhang L, Yu X, Huo L, et al. · Eur Radiol 2019 · Meta-Analysis, Systematic Review
- Comparison of gadobenate dimeglumine and gadopentetate dimeglumine for Breast MRI Screening: a meta-analysis.
Yang XP, Han YD, Ye JJ, et al. · Asian Pac J Cancer Prev 2014 · Comparative Study, Meta-Analysis
- Beta-Catenin-Mutated Hepatocellular Adenomas at Hepatobiliary Phase MRI: A Systematic Review and Meta-Analysis.
Shen L, Altmayer S, Tse JR · J Magn Reson Imaging 2024 · Meta-Analysis, Systematic Review
- Evaluation of four injection profiles for uniform contrast-enhanced signal intensity profiles in MR angiography.
Maki JH, Wilson GJ, Clark TJ · J Magn Reson Imaging 2019 · Randomized Controlled Trial, Research Support, Non-U.S. Gov't
- Contrast-enhanced MRI of carotid atherosclerosis: dependence on contrast agent.
Kerwin WS, Zhao X, Yuan C, et al. · J Magn Reson Imaging 2009 · Clinical Trial, Research Support, N.I.H., Extramural
Sponsor: Bracco
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.